Results of a reevaluation of cardiovascular outcomes in the RECORD trial

被引:137
|
作者
Mahaffey, Kenneth W. [1 ]
Hafley, Gail [1 ]
Dickerson, Sheila [1 ]
Burns, Shana [1 ]
Tourt-Uhlig, Sandra [1 ]
White, Jennifer [1 ]
Newby, L. Kristin [1 ]
Komajda, Michel [2 ,3 ]
McMurray, John [4 ]
Bigelow, Robert [1 ]
Home, Philip D. [5 ]
Lopes, Renato D. [1 ]
机构
[1] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA
[2] Univ Paris 06, Paris, France
[3] Hop La Pitie Salpetriere, Paris, France
[4] Univ Glasgow, Glasgow, Lanark, Scotland
[5] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
关键词
INFARCTION END-POINTS; MYOCARDIAL-INFARCTION; DIABETES-MELLITUS; PRIMARY PREVENTION; CARDIAC OUTCOMES; CLINICAL-TRIAL; TYPE-2; ROSIGLITAZONE; DISEASE; EVENTS;
D O I
10.1016/j.ahj.2013.05.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The US Food and Drug Administration (FDA) required a reevaluation of cardiovascular (CV) outcomes in the RECORD trial. This provided an opportunity to assess the implications of event adjudication by 2 groups and quantify the differences as well as to use new FDA end point definitions in development. Methods Original data were used to systematically identify all potential deaths, myocardial infarctions (MIs), and strokes. Site investigators were approached for additional source documents and information about participants lost to follow-up. Suspected events were adjudicated using standard procedures, and the results were compared with the original trial outcomes. Results Follow-up for mortality was 25,833 person-years, including an additional 328 person-years identified during the reevaluation effort. A total of 184 CV or unknown-cause deaths (88 rosiglitazone, 96 metformin/sulfonylurea), 128 participants with an MI (68 rosiglitazone, 60 metformin/sulfonylurea), and 113 participants with a stroke (50 rosiglitazone, 63 metformin/sulfonylurea) were included. The hazard ratio (HR) for rosiglitazone versus metformin/sulfonylurea for the end point of CV (or unknown cause) death, MI, or stroke was 0.95 (95% CI 0.78-1.17) compared with 0.93 (95% CI 0.74-1.15) for the original RECORD results. Treatment comparisons for MI (HR 1.13, 95% CI 0.80-1.59) and mortality (HR 0.86, 95% CI 0.68-1.08) were also the same compared with the original RECORD results. Sensitivity analyses were also consistent with the original RECORD results. Analyses using the FDA definitions showed similar results. Conclusions Only a modest number of additional person-years of follow-up were ascertained from this reevaluation of CV end points in RECORD. Observed HRs and CIs from these analyses using the original RECORD or new FDA end point definitions showed similar treatment effects of rosiglitazone compared with the original RECORD results.
引用
收藏
页码:240 / +
页数:11
相关论文
共 50 条
  • [21] Severe hypoglycaemia, cardiovascular outcomes and death: Experience from the 'Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results' (LEADER) trial
    Bain, S.
    Zinman, B.
    Marso, S. P.
    Christiansen, E.
    Calanna, S.
    Rasmussen, S.
    Buse, J. B.
    DIABETIC MEDICINE, 2018, 35 : 11 - 11
  • [22] Relationship of Albuminuria and Renal Artery Stent Outcomes: Results From the CORAL Randomized Clinical Trial (Cardiovascular Outcomes With Renal Artery Lesions)
    Murphy, Timothy P.
    Cooper, Christopher J.
    Pencina, Karol M.
    D'Agostino, Ralph
    Massaro, Joseph
    Cutlip, Donald E.
    Jamerson, Kenneth
    Matsumoto, Alan H.
    Henrich, William
    Shapiro, Joseph I.
    Tuttle, Katherine R.
    Cohen, David J.
    Steffes, Michael
    Gao, Qi
    Metzger, D. Christopher
    Abernethy, William B.
    Textor, Stephen C.
    Briguglio, John
    Hirsch, Alan T.
    Tobe, Sheldon
    Dworkin, Lance D.
    HYPERTENSION, 2016, 68 (05) : 1145 - 1152
  • [23] Liraglutide and renal outcomes in Type 2 diabetes: results of the 'Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results' (LEADER) trial
    Poulter, N.
    Mann, J. F. E.
    Brown-Frandsen, K.
    Daniels, G. H.
    Kristensen, P.
    Nauck, M. A.
    Nissen, S. E.
    Pocock, S.
    Buse, J. B.
    Petrie, J.
    DIABETIC MEDICINE, 2017, 34 : 23 - 24
  • [24] Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial
    Holme, I.
    Fayyad, R.
    Faergeman, O.
    Kastelein, J. J. P.
    Olsson, A. G.
    Tikkanen, M. J.
    Larsen, M. L.
    Lindahl, C.
    Holdaas, H.
    Pedersen, T. R.
    JOURNAL OF INTERNAL MEDICINE, 2010, 267 (06) : 567 - 575
  • [25] Cardiovascular Outcomes Among Patients With Acute Coronary Syndromes and Diabetes in India: Results From ACS QUIK Trial
    Alfaddagh, Abdulhamied
    Khraishah, Haitham
    Kassab, Mohamad
    McMillan, Zeb
    Albaghdadi, Mazen
    CIRCULATION, 2021, 144
  • [26] THE SOUTH AMERICAN MAMMALIAN MESOZOIC RECORD: A BIOGEOGRAPHIC REEVALUATION
    Rougier, Guillermo
    Paez, Natalia
    Gaetano, Leandro
    JOURNAL OF VERTEBRATE PALEONTOLOGY, 2008, 28 (03) : 134A - 134A
  • [27] Cardiovascular Outcomes Among Patients with Acute Coronary Syndromes and Diabetes: Results from ACS QUIK Trial in India
    Alfaddagh, Abdulhamied
    Khraishah, Haitham
    Romeo, Giulio R.
    Kassab, Mohamad B.
    McMillan, Zeb
    Chandra-Strobos, Nisha
    Blumenthal, Roger
    Albaghdadi, Mazen
    GLOBAL HEART, 2024, 19 (01) : 37
  • [28] Semaglutide and cardiovascular outcomes by blood pressure in the SELECT trial
    Verma, Subodh
    Deanfield, John
    Arbel, Yaron
    Cariou, Bertrand
    Matos, Ana Laura S. A.
    Hovingh, G. Kees
    Jeppesen, Ole Kleist
    Kahn, Steven
    Latkovskis, Gustavs
    Lingvay, Ildiko
    Maeng, Michael
    Maher, Vincent
    Parkhomenko, Oleksandr
    Poulter, Neil
    van de Borne, Philippe
    Kure, Peter
    Lincoff, Abraham
    CIRCULATION, 2024, 150
  • [29] Predicted efficacy of Inclisiran compared to active comparators on Cardiovascular Outcomes in patients with established atherosclerotic cardiovascular disease: results from the In Silico SIRIUS trial
    Cariou, Bertrand
    Angoulvant, Denis
    Amarenco, Pierre
    Bastien, Alexandre
    Bechet, Emmanuelle
    Boissel, Jean-Pierre
    Courcelles, Eulalie
    Filipovics, Anne
    Granjeon-Noriot, Solene
    Kahoul, Riad
    Mahe, Guillaume
    Peyronnet, Emmanuel
    Portal, Lolita
    Wang, Yishu
    Steg, Philippe
    Boccara, Franck
    CIRCULATION, 2024, 150
  • [30] ACCOMPLISH trial results show fewer cardiovascular events
    Lyon, Sue
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2008, 69 (05) : 253 - 253